Circ J. 2010 May;74(5):852-3. doi: 10.1253/circj.cj-10-0301. Epub 2010 Apr 17.
Ischemic cardiovascular diseases remain among the most serious health challenges worldwide, despite many breakthroughs in cardiovascular medicine. Recently, approaches using stem or progenitor cells to regenerate these ischemic cardiovascular tissues have emerged as a novel therapeutic option. Currently, various bone marrow (BM)-derived cells including endothelial progenitor cells (EPCs) are being investigated to regenerate or repair ischemic myocardium or limbs depending on the type of disease and the differentiation characteristics of specific stem or progenitor cell populations. The issue has been raised, however regarding the use of animal serum for generation of stem or progenitor cells ex vivo. The use of human serum is a promising alternative for clinical therapy.
尽管心血管医学取得了许多突破,但缺血性心血管疾病仍然是全球面临的最严重的健康挑战之一。最近,使用干细胞或祖细胞来再生这些缺血性心血管组织的方法已经成为一种新的治疗选择。目前,正在研究各种骨髓(BM)来源的细胞,包括内皮祖细胞(EPC),根据疾病的类型和特定干细胞或祖细胞群体的分化特征,来再生或修复缺血性心肌或肢体。然而,在体外生成干细胞或祖细胞时使用动物血清的问题已经被提出。使用人血清是临床治疗的一种有前途的替代方法。